Skip to main content
. 2022 Mar 15;33(3):200–206. doi: 10.1097/DER.0000000000000845

Figure 2.

Figure 2

Evidence map of the studies on systemic therapy of AD in people with HIV, viral hepatitis B or C, liver disease, renal disease, or a history of malignancy.